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Pluripotent embryonic stem cells (ESCs) and cancer cells 
share traits and molecular mechanisms, such as the ability to 
self-renew and a block in cellular differentiation. Both ESCs 
and tumor cells have a large proliferative capacity and 
cellular plasticity. One common denominator linking these 
two cell types is the BET family member, BRD4. BRD4 
plays a critical role in gene regulation, recruiting the active 
form of Positive Elongation Factor b (P-TEFb) to RNA 
polymerase II at paused promoters ultimately resulting in the 
production of elongated mRNAs. BRD4 is deregulated in 
many cancers making it an attractive therapeutic target. Here, 
we highlight the recent findings coupling the role of BRD4 in 
pluripotency and tumorigenesis.  
BRD4 in gene regulation 
BRD4 is a member of the BET (bromodomain and 
extraterminal domain) tandem bromodomain-containing 
family that binds acetylated histones H3 and H4 and 
influences gene regulation [1]. BRD4 was originally identified 
as a mitotic chromosome-binding protein that remains 
associated with acetylated chromatin throughout the entire 
cell cycle [2, 3]. This unique property makes BRD4 a 
candidate for mitotic or epigenetic bookmarking after cellular 
division.  Prior to mitosis the nuclear envelope breaks 
down, the chromatin condenses, most regulators separate 
from the mitotic chromosomes, and transcription ceases [4]. 
After mitosis, the genes have a remarkable memory through 
chromatin factors that “bookmark” genes to be expressed or 
silenced resuming the same gene expression patterns 
indistinguishable from the mother cell prior to cellular 
division [5]. 
RNA polymerase II (RNA Pol II) elongation is a 
rate-limiting step in gene transcription [6]. At many 
developmental genes RNA Pol II stalls or pauses after the 
synthesis of a nascent transcript about 30-65 nucleotides in 
length [7]. In human ESCs, nearly 30% of genes transcription 
undergoes a transcriptional pausing [8]. This suggests that 
transcriptional pausing and elongation are additional 
checkpoints control during development [9]. To relieve RNA 
Pol II pausing and enter the productive mRNA elongation 
state, additional proteins such as BRD4 are necessary to 
reverse the stalled RNA Pol II.  BRD4 directly influences 
gene transcription associating with positive elongation factor 
b (P-TEFb) [10, 11]. The BRD4-P-TEFb interaction enhances 
RNA pol II, releases transcriptional pausing, and mediates 
productive elongated mRNAs. The recruitment of BRD4 and 
P-TEFb mediates elongation by phophorylating serine 2 on 
RNA Pol II’s carboxy terminal domain and releasing the 
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pausing factors NELF (Negative Elongation Factor) and 
DSIF (DRB-sensitivity-inducing factor) [6, 7].  
BRD4 in oncogenesis 
In addition to its role in gene regulation, BRD4 is 
important for human disease. BRD4 is a target for 
viral-encoded regulators in human immunodeficiency virus 
and human papillomavirus allowing these infectious agents 
to hijack the cellular machinery facilitating selective viral 
genome integration during mitosis [12,13]. BRD4 deregulation 
is linked to numerous cancers. Cancer cells often exploit the 
host cell’s transcriptional and chromatin regulatory 
machinery to propagate their oncogenic gene expression 
profiles. NUT midline carcinoma (NMC) is a group of 
malignant and highly lethal cancers, arising from 
chromosomal translocations involving the NUT (Nuclear 
protein in Testis) gene on chromosome 15q14 [14]. In the 
majority of NMC cases, the NUT-containing chromosome 
translocates to the Brd4 gene on chromosome 19 [14]. This 
BRD4-NUT protein fusion results in a poorly differentiated 
and highly aggressive carcinoma with a mean survival of six 
months.  Besides NMC, BRD4 deregulation is found in 
leukemia, hepatocellular carcinoma, breast cancer, and brain 
cancers [15-17]. BRD4’s function in cancer is associated with 
epithelial-to-mesenchymal transition (EMT) [18], stem 
cell-like conversion, and primary stress responses.  BRD4 
protects chromatin from DNA damage signaling, further 
implicating its role as gatekeeper in normal cells and 
oncogenesis [19]. 
Indeed, BRD4 is a therapeutic target for multiple cancers.  
Small-molecule inhibition of BRD4’s bromodomains or 
targeting small interfering hairpin RNAs eliminates several 
malignant cancer cells including leukemia, melanoma, 
prostate, and breast cancers [15, 16, 20-27]. Pharmacological 
inhibition of BET bromodomain proteins with small 
molecules (such as JQ1 and I-BETs) interferes with BRD4’s 
requirement for enhancer function and transcriptional 
elongation in different cancers [15, 28, 29]. The inhibition of 
BRD4 is accompanied by terminal differentiation through 
down regulation of c-MYC, a factor that regulates 
transcriptional pause release and important for tumor 
viability [15, 29]. Recently BRD4 was found to control 
HOTAIR, a long noncoding RNA essential for glioblastoma 
proliferation [30]. This suggests BRD4 may be a therapeutic 
target in Glioblastoma Multiforme one of the most common 
and aggressive malignant adult brain tumors. 
Converging themes in pluripotent and cancer cells 
Both pluripotent and cancer cells have common features 
such as rapid cell cycles, featuring a diminution of G1 phase, 
and high telomerase activity [31]. Together, these can result in 
uncontrolled cellular proliferation. ESCs and cancer cells 
have a loss of G1 cell cycle checkpoint after DNA damage 
[32]. The plasticity of their cell type is underscored as upon 
transplantation into immunodeficient mice where both ESCs 
and cancer cells form benign and malignant tumors, 
respectively [33]. Notably both have changes in epithelial and 
mesechymal states. Epithelial-to-mesenchymal transition 
(EMT) and mesenchymal-to-epithelial transition (MET) 
regulate cellular plasticity during embryonic development 
and in oncogenesis [34]. EMT is a process in which polarized 
cell lose their cell-cell adhesion, become mobile and invasive 
gaining mesenchymal features. EMT in cancer cells 
contributes to tumor development, invasion, dissemination, 
and resistance to therapies [34]. The Twist transcription factor 
is a key activator of EMT. Twist has a diacetylated histone 
H4-like domain that recruits BRD4. Together this 
Twist-BRD4 interaction directs gene expression in basal-like 
breast cancer [26]. Disruption of the BRD4-diacetylated Twist 
interactions with BET inhibitors can suppress tumorigenesis 
in basal-like breast cancer [26]. 
MET is a reversal of epithelial characteristics and in 
oncogenesis is associated with metastases [34]. In normal 
development, stem cells are at the top of the somatic lineage 
hierarchy and utilize both EMT and MET to generate all of 
the embryonic germ layers: ectoderm, endoderm, and 
mesoderm.  Optimal epigenetic reprogramming from the 
somatic state to induced pluripotency requires a sequential 
Figure 1. Model of BRD4 action in pluripotency. BRD4 interacts 
with P-TEFb resulting in the phosphorylation of RNA Pol II serine 2 
(Ser 2), a release from pausing of the nascent RNA strand, and the 
productive transcriptional elongation of the pluripotency related 
genes.  Inhibition of BRD4 with a BET inhibitor, JQ1, or depletion of 
BRD4 by knockdown ablates the production transcription of the 
pluripotency genes. RNA Pol II is unable to elongate as evident by 
the presence of serine 5 (Ser 5) phosphorylation and a lack of Ser 2 
phosphorylation.  This results in a shift away from pluripotency and 
differentiation to the neuroectoderm cell fate. 
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EMT-MET mechanism. The tumor suppressor protein p53 is 
frequently mutated in cancers and can modulate epithelial 
and mesenchymal states [34-37]. P53 is a barrier to somatic cell 
reprogramming, whereas mutations in p53 augment 
epigenetic reprogramming in induced pluripotency [38-40]. The 
p53 somatic reprogramming block is mediated by inhibition 
of MET [41]. Interestingly BRD4 interacts with p53 resulting 
in a phosphorylation switch, targeting both proteins to 
acetylated chromatin for gene-specific activation [42]. 
The master regulators OCT4, SOX2, c-MYC, and KLF4 
control the pluripotent gene expression during 
embryogenesis, in ESCs, and induced pluripotent stem cells 
(iPSCs). The exciting discovery by Yamanaka’s group 
demonstrated that the expression of these four transcription 
factors in fibroblast somatic cells converts them to iPSCs [43]. 
Interestingly, these core stem cell transcription factors are 
upregulated in several types of human cancers.  OCT4 is 
expressed in pancreatic cancer, oral squamous cell 
carcinoma, seminoma, and bladder cancer [33, 44-48]. SOX2 
overexpression results in cancer stem cell-like characteristics, 
which influence tumor formation and aggressiveness in 
squamous cell carcinoma, lung cancer, serous ovarian 
cancers, gastric cancer, pancreatic cancer, and brain cancers 
[49-53]. Indeed, SOX2 is associated with chemotherapy and 
tamoxifin resistance in breast cancer [50-53]. In addition to its 
role in induced pluripotency, KLF4 is believed to act as an 
oncogene in breast cancer [54]. The transcription factor 
c-MYC is a well-known mediator in oncogenesis and is 
activated in nearly 70% of all human cancers [55]. A c-MYC 
protein network accounts for the similarities between ESC 
and cancer stem cell transcriptional programs [56].  
Cancer cells exhibit an increased utilization of glycolysis 
for carbon metabolism, rather than mitochondrial oxidative 
phosphorylation even in the presence of oxygen [57]. This 
phenomenon is called the “Warburg effect”, a 
pyruvate-lactate metabolism that rapidly generates ATP, is 
observed in numerous tumors reflecting their highly 
proliferative state. Similarly, pluripotent ESCs prefer a 
glycolysis metabolism [58-60]. Within hours of ESC cellular 
differentiation, a metabolic switch occurs and oxidative 
phosphorylation dominates [57]. The ESC glycolytic step 
differs from the Warburg effect (a metabolic pyruvate-lactate 
step), in that a pyruvate-acetyl CoA step enhances the high 
rates of cytosolic acetyl-CoA synthesis proposed to maintain 
the levels of histone acetylation post-translational 
modification (PTM) necessary for pluripotency [61]. These 
studies further extend the connection in ESCs between 
metabolic intermediates and an open or permissive chromatin 
state. 
Pluripotent and cancer cells have distinctive epigenetic 
profiles. One highlight is the status of X-chromosome 
inactivation (XCI), a crucial epigenetic process that silences 
one of the two female Xs to balance the gene dosage with 
XY males [62]. XCI is tightly linked with pluripotency, with 
epigenetic silencing commencing during cellular 
differentiation. In contrast, a global reprogramming and 
reactivation of the silenced X [63-64] accompany the 
conversion of female somatic cells to iPSCs. In 
undifferentiated ESCs, the long noncoding RNAs (lncRNAs) 
Xite (the enhancer for Tsix), Tsix (the anti-sense repressor of 
Xist), and Xist (the silencer) are all expressed on the single 
male X and both female X-chromosomes [62]. Following 
cellular differentiation, the male X extinguishes the 
expression of these lncRNAs to retain a single, active X 
(Xa). Differentiating female ESCs have a choice of active 
(Xa) versus inactive X (Xi). On the future Xa, Xite and Tsix 
expression keep the silencer lncRNA Xist levels low.  On 
the future Xi, Xist and Tsix are extinguished resulting in a 
robust upregulation of Xist levels [62]. Xist subsequently 
recruits heterochromatic silencing factors. OCT4 lies at the 
top of the XCI hierarchy regulating the 
pluripotent-associated lncRNAs Xite and Tsix [65]. OCT4 
partners with the chromatin insulator, CTCF, specifying the 
early decision of XCI counting (XCI occurs when there is 
more than one X), X-X homologous pairing (a chromosomal 
dance necessary for XCI), and choice (the mutually exclusive 
decision of active versus inactive X) [65]. This epigenetic 
memory is observed in XCI as once chosen for activation or 
inactivation, the same female X-chromosome retains its fate 
after cell division.    
Pluripotent and cancer cells both display an epigenetic 
ground state with hypomethylation and a paucity of PTM 
silent marks such as histone 3 lysine 27 trimethylation 
(H3K27me3) that decorates the inactive X-chromosome in 
differentiated female cells [62]. For nearly sixty years it has 
been observed that the Barr body, the heterochromatic 
inactive X-chromosome is lacking in the nuclei of breast and 
ovarian cancers [66].  
Oxygen status is crucial for human ESCs and 
tumorigenesis. The presence of two active female 
X-chromosomes (XaXa) exemplifies the ground state of 
pluripotency in mouse ESCs [63]. Human female ESCs show 
invariable XCI status (exhibiting partial or complete XCI) 
due to their advanced developmental stage during derivation 
as well as between subcultures of a single human ESC line 
[67]. The epigenetic ground state of human ESCs (XaXa) is 
obtained during derivation and culture upon exposure to 
physiological levels of oxygen, suggesting that oxygen 
maintains a more developmental immature state [67]. Thus, 
the ground state of epigenetics (XCI) in human ESCs is 
established by increasing oxygen. Tumor cells frequently 
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outgrow their normal blood supply and develop hypoxia and 
hypoglycemia. This results in a series of events in which 
cancer cells take advantage of the normal cellular stress 
response.  Normal cells respond to the hypoxia by increased 
tissue oxygenation to stabilize homeostasis. In contrast, 
tumor cells engage a vicious cycle of growth and starvation 
[68]. The overall result is that hypoxia increases tumor 
aggression and metastasis. Overall, an ESC-like signature is 
present in poorly differentiated tumors [31]. The parallels that 
link the pluripotent and tumor cell types are of huge interest. 
A commonality is the BET family member BRD4. 
BRD4 is crucial for pluripotent gene expression and the 
lncRNAs that regulate XCI. 
Although BRD4 is known to play crucial roles in cancers, 
very little is known about its function in normal 
development.  Mutation of the mouse Brd4 results in a 
peri-implantation lethal [69]. This is a crucial time during 
lineage segregation with the formation of the pluripotent 
epiblast (the source of ESCs and the embryo proper) and 
female X-chromosome inactivation (XCI) establishment, a 
crucial epigenetic process that silences the dosage disparity 
between XX females and XY males [63]. Taken together, 
these results suggest that BRD4 may play a role in both of 
these early development processes. Therefore, we postulated 
that BRD4 interacts with pluripotent factors and functions in 
the coupled processes of pluripotency and XCI. Indeed, we 
discovered that BRD4 physically interacts with OCT4 in 
ESCs.  We determined that male and female ESCs show 
similar BRD4 protein levels during cellular differentiation at 
differentiation day 0 (pre-XCI), day 4 (time of XCI 
establishment), and day 8 (post-XCI) [70]. This is in contrast 
to OCT4 expression, which shows a diminution of protein 
expression upon differentiation. The OCT4 transcription 
factor directly regulates the XCI lncRNAs Xite and Tsix. 
OCT4 triggers X-chromosome pairing and counting [65]. 
During the shift away from pluripotency by removal of 
leukemia inhibitory factor (LIF) and mouse embryonic feeder 
layers, the lncRNAs Xite and Tsix are extinguished.  In 
contrast, upon differentiation the silencer Xist is robustly 
expressed reflective of XCI. These XCI lncRNAs are 
transcribed in both the sense and anti-sense orientation 
suggesting that tight control of RNA Pol II is necessary for 
their regulation.  
OCT4 is a master regulator of the pluripotent fate 
targeting Xite, Tsix, Nanog, Sox2, and Oct4 itself [65, 71-73]. As 
ESCs differentiate, the chromatin shifts from a 
transcriptionally permissive euchromatic or “open state” to a 
more heterochromatic or “closed state” [74-76]. These 
chromatin changes are exemplified by alterations in histone 
PTMs, chromatin configuration, the presence of the 
Polycomb group proteins, and gene expression [77, 78]. In 
ESCs both OCT4 and BRD4 occupy the regulatory regions 
of pluripotent genes such as Nanog, Oct4, Sox2, Xite, and 
Tsix [70]. Using an OCT4-regulated ESC line [79], we 
determined that OCT4 recruits BRD4 to selective regulatory 
regions such as the Nanog promoter [70].  
The small molecule, JQ1, which selectively binds the 
bromodomains, can inhibit the BET domain proteins [15, 28]. 
We posited that inhibition of BRD4 by JQ1 alters the 
pluripotent status in ESCs.  First, we performed a dose 
curve of JQ1 in male and female ESCs.  Interestingly, JQ1 
inhibits c-MYC protein as previously reported but in addition 
we demonstrated that OCT4 levels are decreased [70]. Next, 
we queried BRD4, P-TEFb, and histone H4 acetylation status 
at pluripotent regulatory regions in ESCs using quantitative 
Chromatin immunoprecipitation. (qChIP). JQ1 exposure 
specifically displaces BRD4 and P-TEFb occupancy without 
altering H4 acetylation levels [70]. The BET inhibition 
diminished pluripotent gene expression, shifting the cell fate 
of the treated ESCs to neuroectoderm identity. In contrast, 
the RNA Pol II inhibitors Hexim1 and Sens3 were 
upregulated suggesting that BRD4 represses these genes [70]. 
JQ1 exposure in differentiated female cells greatly 
diminishes Xist lncRNA expression but does not reactivate 
genes along the silent X-chromosome. Consistent with the 
JQ1 treatment, loss of Brd4 by small interfering RNAs 
(siRNAs) in ESCs reduces the expression of pluripotent 
genes as well as Xite and Tsix [70]. Overexpression of the 
BRD4 in ESCs enhances the levels of pluripotent genes.  
These results support the findings of DiMicco et al. for a role 
of BRD4 in human ESCs [80]. Taken together, our results 
suggest that BRD4 activates the pluripotent and XCI genes in 
ESCs.  BRD4 maintains ESC identity and fate. 
Conclusion   
Herein we have summarized similarities and differences 
between pluripotent and stem cells. We have highlighted the 
recent findings for BRD4 and stem cell identity. However 
many outstanding questions remain. Such as is BRD4 
involved in X-X chromosome pairing? Does BRD4 provide 
the epigenetic memory for female XCI fate retaining the 
same active and inactive X-chromosomes after cellular 
division?  Our understanding of how BRD4 functions in 
normal developmental processes is crucial for elucidating its 
deregulation in cancers. 
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